Court Preliminarily Approves Plan to Pay Consumers From $96.5 Million in Generic Drug Price-Fixing Settlements; NC Attorney General Urges Claims by March 8, 2027
North Carolina Attorney General Jeff Jackson and 47 other states and territories say people who bought certain generic drugs between May 2009 and December 2019 can now file claims, while the drugmakers that settled deny any wrongdoing.
The Fine Print in a $96.5 Million Settlement
North Carolinians who bought certain generic drugs between May 2009 and December 2019 can now file a claim for a piece of a $96.5 million pot. Attorney General Jeff Jackson's office is urging eligible residents to do it before the deadline hits[1]. A federal court in Connecticut just gave preliminary approval to the plan[2].
But six drug companies are putting up that money without admitting they did anything wrong. The settlement's own FAQ says the defendants "deny they did anything wrong[12]." That's not unusual in these cases. It's also not the whole story.
The number that gets top billing, $96.5 million, comes from six separate companies settling at different times over two years: Heritage and Apotex in 2024, Lannett and Bausch earlier in 2026, and Glenmark in July[7][10][13]. None of them are the biggest names in the underlying lawsuit. That's the detail that explains almost everything else about this story.
What $96.5 Million Actually Buys
The states' case goes back to 2016. Attorneys general accuse generic drug executives of splitting up customers and coordinating on prices through meetings, calls, emails, and texts, instead of competing[12][17]. Jackson called it "a massive scheme with a lot of players working together to raise drug costs for you and raise profits for themselves[8]."
The six companies that just settled aren't the main targets. Teva, Sandoz, and Novartis are still fighting the case[5][13][17]. Most of the settling companies made their deals early, and as part of those deals, they agreed to help the states build their case against the bigger players still standing[7][10].
That's the mechanism worth understanding: it's called cooperation-for-leniency. A smaller company pays less money up front and hands over evidence, in exchange for helping prosecutors go after the larger targets. It's a common move in big antitrust cases, and it explains why a decade of nationwide generic drug sales has produced a settlement fund this size so far.
The scale gap shows up clearly next to the other numbers in play. Sandoz already agreed to a $400 million deal in principle with 43 states, still awaiting court approval — more than four times the money being distributed right now[5][6]. A separate private class action, unrelated to the states' case, is worth about $533 million and has its own November 9, 2026 deadline[11]. Both dwarf what's actually landing in mailboxes this fall.
Two True Numbers, Two Different Stories
Here's where the coverage gets confusing, and it starts with North Carolina's own numbers. The Glenmark settlement totaled $29.6 million nationwide. North Carolina's actual share of that was just over $700,000[8].
Several outlets reported it differently. FOX8 WGHP's headline credited North Carolina with the full $29.6 million[14]. The North State Journal cited $66.95 million as the state's total — but that figure is actually the combined nationwide total from two earlier settlements, Heritage/Apotex's $49.1 million plus Lannett/Bausch's $17.85 million[8][10][13]. Even Jackson's own office posted the same $66.95 million figure as North Carolina's "total recoveries" on social media, so the mix-up wasn't confined to one outlet.
The pattern repeats with the Sandoz deal. The Detroit News described the $400 million agreement as settled, using "to pay" in its headline[16]. State AG releases are more precise: it's a settlement in principle, and it still needs a judge's sign-off[5][6].
None of this is really the outlets' fault alone. Nearly every article on this story is built from a state attorney general's press release, and coalition members in nearly every state, Republican and Democrat alike, put out nearly identical language the same week[1][2][19]. STAT, a health-industry trade outlet, stuck closer to attributed language, calling it a "long-running battle" rather than settled fact[9].
What the Companies Aren't Saying, and Why
The settling companies — Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage's parent Emcure — have offered essentially one public statement each: a denial buried in a settlement FAQ[12]. That's a deliberate choice, not an oversight.
Settling without admitting fault protects a company on two fronts. It caps years of legal costs and removes uncertainty about how a trial might go. It also blocks a court finding of wrongdoing that private plaintiffs in other lawsuits could reuse against them.
From the companies' side, this is a business calculation, not a confession. The generic drug market during those years also saw real price pressure from buyer consolidation and supply shortages, forces the industry has long pointed to when prices moved. None of the news coverage found in this review, in the U.S. or abroad, included a company statement beyond that single denial. Two of the six companies, Glenmark and Emcure, are based in India, and Indian business media appear not to have covered the claims launch at all — treating it, it seems, as a minor U.S. legal cost rather than news.
Where the Money Actually Goes
Suppose you filed a claim and qualified. How much of that $96.5 million pie is actually headed to consumers? Court filings on the settlement funds answer that, and the number is smaller than the headline suggests.
Of the $29.6 million Glenmark fund, about $8.9 million is set aside for settlement administration and to reimburse the states' own litigation costs and fees, before any money reaches a single consumer[20]. The Lannett and Bausch fund tells the same story: $5.2 million of its $17.85 million total goes to those same costs[20]. That's roughly 30% of each fund, gone before distribution even starts.
Spread the remainder across a nationwide pool of buyers going back to 2009, and the math gets harder for any one person. Individual payments will likely be modest. None of the announcements reviewed here specify exactly how much a typical claimant should expect.
That gap in the coverage matters. No national outlet, left or right, dug into where the settlement money actually goes before it reaches consumers. The sharpest "conspiracy" language in this entire story comes not from journalists but from the attorneys general themselves, a bipartisan group that includes Democrats like California's Rob Bonta and Republicans like Nebraska's Mike Hilgers[19]. Filing a claim is free and takes little paperwork. Understanding exactly what it's worth may take more digging than any of the coverage so far has offered.
Summary
A federal court in Connecticut has preliminarily approved a plan to pay consumers out of settlements with six generic drug makers. North Carolina Attorney General Jeff Jackson is now urging state residents to file claims[1][2]. The six companies are Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage's parent company, Emcure. Together they agreed to pay about $96.5 million[1][2]. People who bought a listed generic drug between May 2009 and December 2019 may qualify. They can check at AGGenericDrugs.com or call 1-866-290-0182[1].
The money comes from lawsuits filed by a coalition of 48 states and territories: North Carolina plus 47 others. The coalition is led by Connecticut and includes both Democratic and Republican attorneys general[1][2][6]. The dek's '48-state coalition' is shorthand, since territories are part of the count. The states accuse drug company executives of using meetings, calls, emails, and texts to split up customers and raise prices instead of competing[12][17]. Claims are due March 8, 2027. Anyone who wants to opt out or object must do so by Oct. 15, 2026. A final approval hearing is set for Nov. 5, 2026, in Hartford[2][4].
The main point in dispute is whether a conspiracy happened at all. The states call it a 'massive scheme'[8]. Every settling company agreed to pay without admitting wrongdoing. The settlement's own FAQ says the drugmakers 'deny they did anything wrong'[12]. These companies are not the main targets. Most of them settled early and promised to help the states build their case against the larger defendants still in the lawsuits[7][10]. That helps explain why a case covering a decade of drug sales has produced a fund this small so far. It is also separate from a pending $400 million deal with Sandoz and from a private class action worth about $533 million, which has its own Nov. 9, 2026 deadline[5][11].
The Event
On or about Sept. 22–25, 2026, attorneys general across the country announced that the U.S. District Court for the District of Connecticut had preliminarily approved a plan to distribute about $96.5 million from settlements with Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure[2][3][15]. North Carolina Attorney General Jeff Jackson's office issued its own release urging eligible residents to file claims[1]. Claims are due March 8, 2027, and a final approval hearing is scheduled for Nov. 5, 2026[2][4].
Undisputed Facts
- A federal court in Connecticut granted preliminary approval of the states' plan to distribute money from the six manufacturer settlements[2].
- The settlements add up to about $96.5 million: $49.1 million from Heritage and Apotex (2024), $17.85 million from Lannett and Bausch (2026), and $29.6 million from Glenmark (July 15, 2026)[10][13][7].
- People who bought a listed generic drug between May 1, 2009, and Dec. 31, 2019, may be eligible; claims are due March 8, 2027[1][4].
- The opt-out and objection deadline is Oct. 15, 2026, and the final approval hearing is Nov. 5, 2026, in Hartford[2].
- The settling companies deny wrongdoing; the settlement FAQ states that 'the Defendant drug manufacturers deny they did anything wrong'[12].
- As part of their deals, the settling companies agreed to cooperate in the states' continuing lawsuits against other manufacturers and executives[7][10].
- Separately, 43 states and territories, including North Carolina, reached a $400 million settlement in principle with Sandoz in August 2026, which still needs court approval[5][6].
- North Carolina's share of the Glenmark settlement was reported as more than $700,000[8].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- Cooperation-for-leniency
- The small early settlements are a litigation tactic. Companies pay less and hand over evidence, and the states use it against larger defendants like Teva and Sandoz[7][10][5].
- Settle without admitting
- Companies settle to cap costs and avoid findings that private plaintiffs could reuse. So every settlement comes with a formal denial[12][11].
- Visible refunds for elected officials
- Attorneys general in both parties gain from promoting consumer refunds, so identical releases went out in many states in the same week[1][2][19].
Material realityAbout $96.5 million is available for a decade of purchases (2009–2019) across a nationwide pool of buyers, so individual payments are likely to be small[2][4]. Court filings show a substantial share of each settlement fund is earmarked for administration and legal costs before any money reaches consumers: about $8.9 million of the $29.6 million Glenmark fund and about $5.2 million of the $17.85 million Lannett/Bausch fund are set aside for settlement administration and to reimburse the states' litigation costs and fees, roughly 30 percent of each fund[20]. Much larger sums sit in other tracks. Sandoz's $400 million deal in principle still needs court approval[5]. A separate private class action worth about $533 million has a Nov. 9, 2026 deadline and its own claim rules[11]. The state cases against the remaining large manufacturers are still pending[17].
Narrative as a weaponThe attorneys general control almost all of the public record here. Nearly every story is a local rewrite of a press release, so the 'conspiracy' and 'overpaid' language often appears without attribution. The companies speak only through a one-line denial in a settlement FAQ. Some outlets also blur scale: they describe coalition-wide totals as a single state's recovery, or treat the pending Sandoz deal as final. National and overseas outlets mostly ignored the claims launch, so there is little independent scrutiny of how the money will be split — including how much of each fund goes to administration and litigation costs before consumers are paid.
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asThe states argue that generic drugs are supposed to be the cheap option, and that competition among many makers is what keeps them cheap. When rivals agree not to compete, patients lose the one protection they have. Jackson called it 'a massive scheme with a lot of players working together to raise drug costs for you and raise profits for themselves'[8]. The coalition's view is that returning money to buyers, even in small amounts, puts a price on that behavior. The early settlements also buy evidence against the bigger defendants still in the case[7][10].
WhyThe states want to win or settle the larger claims still pending against Teva, Sandoz, Novartis, and others, and cooperation deals help them do that[5][13][17]. For an elected attorney general, a consumer refund also shows voters a concrete result. Jackson is a Democrat, but the coalition includes Republican attorneys general such as Nebraska's Mike Hilgers[19].
Impact on themIf few people file claims, the effort looks weaker, which is why the offices are promoting the claims process heavily[1][3]. North Carolina gets a modest direct share; its Glenmark share was reported as more than $700,000[8].
Frames it asThe companies deny that they did anything wrong[12]. A company can settle without admitting fault. It may do so to cap years of legal costs and remove uncertainty. It may also want to avoid a court finding that private plaintiffs could use against it in other lawsuits. From that side, a settlement is a business decision, not a confession. The generic drug market also had real price pressures during those years, including buyer consolidation and supply shortages, which companies have long cited to explain price changes.
WhyThey want to get out of a multistate case that started in 2016 and grew into several complaints against dozens of companies and executives[17]. Trading cooperation for a smaller payment limits their exposure[7][10].
Impact on themThey pay about $96.5 million combined and must adopt compliance reforms. They also face separate private class actions; Heritage and Apotex together are part of a $58 million private end-payer deal[11][2].
Frames it asThe defendants still in the case have not been found liable. Sandoz agreed to a $400 million deal in principle, which covers its Swiss affiliates Novartis AG, Sandoz AG, and Sandoz Group AG. That deal needs court approval[5][6].
WhyThey want to resolve the claims on terms that limit their payments and any admissions. Evidence from the cooperating companies makes that harder[7].
Impact on themThe pending Sandoz deal alone is more than four times the $96.5 million now being distributed[5][6].
Frames it asBuyers argue they paid higher prices, through copays, cash purchases, or insurance premiums, for drugs that should have been cheap, and that any refund is overdue.
WhyThey want the money back with little paperwork. They also want to keep this claim separate from the private class action, which has its own deadline and rules[11].
Impact on themThe announcements reviewed for this article do not say how much each claimant will get. A $96.5 million fund spread across a nationwide, decade-long pool of buyers will probably pay individuals modest amounts, further reduced by administration and litigation costs deducted before distribution — roughly 30 percent of the Glenmark and Lannett/Bausch funds, per the settlement agreements[20]. Consumers could also mix it up with the separate $533 million private settlement, whose claim deadline is Nov. 9, 2026[11].
Like this article?
The Bias Ledger average rating 3.7
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| STAT | U.S. center (health/pharma trade) | 2 | Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states | It says 'allegations' and frames the case as a years-long legal fight, which keeps the conspiracy claim attributed. |
| FOX19 | U.S. local (Gray-owned) | 3 | Did you overpay for generic drugs? Claims open for $96.5M settlement | Its consumer-service hook, 'Did you overpay,' assumes the overcharge that the defendants deny. |
| The Detroit News | U.S. center-right (Gannett) | 3 | Drugmaker to pay Michigan, 42 other states $400M in price-fixing case | It presents the Sandoz deal as settled with 'to pay,' though the deal is a settlement in principle that still needs court approval[6]. |
| North State Journal | U.S. right (NC) | 4 | NC secures $700K-plus with Glenmark in drug price-fixing settlement | It stays close to the attorney general's release and quotes. The search summary of its story gives $66.95 million as North Carolina's total, but that matches the coalition-wide total before the Glenmark deal ($49.1M + $17.85M)[8][10][13]. |
| FOX8 WGHP | U.S. local (Nexstar-owned) | 5 | North Carolina receives $29.6 million settlement in pharmaceutical price-fixing conspiracy | The headline credits North Carolina with the full $29.6 million, which was the coalition-wide total; the state's reported share was more than $700,000[8]. It also calls the conspiracy a fact without attribution. |
| Iredell Free News | U.S. local (NC); republishes official releases | 5 | N.C. attorney general urges eligible North Carolinians to claim compensation for certain generic drug purchases | It runs the attorney general's release nearly word for word. That carries the office's 'overpaying' framing without any company response. |
References
- Attorney General Jeff Jackson Urges Eligible North Carolinians to Claim Compensation for Certain Generic Drug Purchases — North Carolina Department of Justice · State government; office of an elected Democratic attorney general
- Attorney General Davenport Urges Consumers to Claim Compensation for Inflated Generic Drug Prices — New Jersey Office of Attorney General · State government; appointed Democratic-administration attorney general; coalition member
- Did you overpay for generic drugs? Claims open for $96.5M settlement — FOX19 (WXIX) · Local TV news, Gray Media-owned; consumer-service framing
- New Yorkers can seek generic-drug settlement payments by March 2027 — Fingerlakes1.com · Independent local news site, New York
- Attorney General Jeff Jackson Reaches $400 Million Settlement in Principle with Sandoz Over Drug Price-Fixing Conspiracy — North Carolina Department of Justice · State government; office of an elected Democratic attorney general
- $400 Million Settlement in Principle with Sandoz in Generic Drug Price-Fixing Litigation — New Hampshire Department of Justice · State government; office of a Republican attorney general; coalition member
- Attorney General Jeff Jackson Reaches $29.6 Million Settlement with Glenmark Over Drug Price-Fixing Conspiracy — North Carolina Department of Justice · State government; office of an elected Democratic attorney general
- NC secures $700K-plus with Glenmark in drug price-fixing settlement — North State Journal · Right-leaning North Carolina newspaper
- Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states — STAT · Health and pharma trade news, Boston Globe Media-owned; center
- Attorney General Phil Weiser announces $49.1 million settlements in ongoing multistate antitrust lawsuit against generic drug manufacturers — Colorado Attorney General · State government; office of a Democratic attorney general; coalition member
- $533M Generic Drug Price-Fixing Settlement — Claim by Nov 9 — Open Class Actions · Commercial class-action settlement aggregator; ad-supported
- Generic drug manufacturers agree to class action settlements: Who can claim and how to file — ClaimDepot · Commercial settlement-claims aggregator; ad-supported
- Attorney General Jeff Jackson Reaches $17.85 Million Settlement with Lannett and Bausch Over Generic Drug Price Fixing; Sues Novartis and Sandoz — North Carolina Department of Justice · State government; office of an elected Democratic attorney general
- North Carolina receives $29.6 million settlement in pharmaceutical price-fixing conspiracy — FOX8 WGHP · Local TV news, Nexstar-owned
- Did you buy generic drugs? You may qualify for settlement money — WCAX · Local TV news, Gray Media-owned, Vermont
- Drugmaker to pay Michigan, 42 other states $400M in price-fixing case — The Detroit News · Gannett-owned daily; historically center-right editorial page
- Attorney General Tong Announces Updates in Litigation Against Generic Drug Manufacturers — Connecticut Office of the Attorney General · State government; Democratic attorney general; coalition lead
- N.C. attorney general urges eligible North Carolinians to claim compensation for certain generic drug purchases — Iredell Free News · Local NC news site; republishes official releases
- Attorney General Mike Hilgers Urges Consumers to Claim Compensation for Inflated Generic Drug Prices — Nebraska Attorney General (via EIN Presswire) · State government; office of a Republican attorney general; coalition member
- FAQ — Generic Drug Antitrust Settlements — AGGenericDrugs.com (court-appointed settlement administrator) · Official settlement documents/administrator site; not a news outlet